-
Views
-
Cite
Cite
Muzamil M Abdel Hamid, Walla M E Abdallah, Maazza Hussien, Niven M Mohammed, Elfatih M Malik, Mohamed E Ahmed, Abdelrahim O Mohamed, Absence of K13 gene mutations among artesunate/sulfadoxine–pyrimethamine treatment failures of Sudanese Plasmodium falciparum isolates from Damazin, southeast Sudan, Transactions of The Royal Society of Tropical Medicine and Hygiene, Volume 113, Issue 7, July 2019, Pages 428–430, https://doi.org/10.1093/trstmh/trz027
- Share Icon Share
Abstract
The emergence of resistant parasites to artemisinin poses a threat to malaria treatment. The study aimed to investigate K13 gene mutations in Plasmodium falciparum artesunate (AS)/sulfadoxine–pyrimethamine (SP) efficacy study in Sudan.
A total of 31 (14 failures and 17 adequate clinical and parasitological response [ACPR]) pretreatment dried blood samples from patients with uncomplicated P. falciparum malaria treated with AS/SP were examined. Nested polymerase chain reaction (PCR) and DNA sequencing of the K13 gene was performed.
PCR products were obtained from 30 (96.8%) samples and sequencing was successful in 28 (90.3%). No mutation of the K13 gene was recorded in the treatment failure group. A single mutation (C>T; A621V) in one ACPR patient sample was detected.
There is no evidence of K13 mutation among AS/SP treatment failure patients. A single mutation of the K13 gene not linked to treatment failure has been detected.
Comments